Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1519-1526

  Lu, Wanlu ^a   Lu, Libing ^a   Feng, Yun ^a   Chen, Jiao ^a   Li, Yan ^a   Kong, Xiangli ^a   Chen, Sixiu ^a   Li, Xiaoyu ^a   Chen, Qianming ^a   Zhang, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Inflammation; Inflammatory cytokines; Oral squamous carcinoma; PD L1; Tumor immune evasion

Indexed keywords

ALLOPHYCOCYANIN; ANTIINFLAMMATORY AGENT; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LIPOCORTIN 5; PHYCOERYTHRIN; PHYTOHEMAGGLUTININ; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CONTACT; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VIVO STUDY; INFLAMMATION; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TUMOR ESCAPE;

EID: 84875696452     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1238     Document Type: Article

References (32)

1. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
2. Aggarwal BB, Shishodia S, Sandur SK, et al: Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621, 2006.
3. Grange JM, Krone B and Mastrangelo G: Infection, inflammation and cancer. Int J Cancer 128: 2240-2241, 2011.
4. Mantovani A and Pierotti MA: Cancer and inflammation: a complex relationship. Cancer Lett 267: 180-181, 2008.
5. Eiró N and Vizoso FJ: Inflammation and cancer. World J Gastrointest Surg 4: 62-72, 2012.
6. Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912, 2008.
7. Tan TT and Coussens LM: Humoral immunity, inflammation and cancer. Curr Opin Immunol 19: 209-216, 2007.
8. Arias JI, Aller MA and Arias J: Cancer cell: using inflammation to invade the host. Mol Cancer 6: 29, 2007.
9. Aggarwal BB and Gehlot P: Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9: 351-369, 2009.
10. Moore MM, Chua W, Charles KA and Clarke SJ: Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 87: 504-508, 2010.
11. Alexandrescu DT, Riordan NH, Ichim ET, et al: On the missing link between inflammation and cancer. Dermatol Online J 17: 10, 2011.
12. Aggarwal BB, Vijayalekshmi RV and Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430, 2009.
13. Babbar N and Gerner EW: Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res 188: 49-64, 2011.
14. Demaria S, Pikarsky E, Karin M, Coussens LM, et al: Cancer and inflammation: promise for biologic therapy. J Immunother33: 335-351, 2010.
15. Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol 23: 515-548, 2005.
16. Nakanishi J, Wada Y, Matsumoto K, et al: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56: 1173-1182, 2007.
17. Sun J, Xu K, Wu C, et al: PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 69: 19-27, 2007.
18. Ghebeh H, Mohammed S, Al-Omair A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198, 2006.
19. Fife BT, Pauken KE, Eagar TN, et al: Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10: 1185-1192, 2009.
20. Blank C, Gajewski TF and Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific Tcells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54: 307-314, 2005.
21. Blank C, Kuball J, Voelkl S, Wiendl H, et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific Tcell responses invitro. Int J Cancer 119: 317-327, 2006.
22. Blank C and Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56: 739-745, 2007.
23. Karwacz K, Arce F, Bricogne C, et al: PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology 1: 86-88, 2012.
24. Chen J, Feng Y, Lu L, et al: Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217: 385-393, 2012.
25. Fan J, Nishanian P, Breen EC, McDonald M and Fahey JL: Cytokine gene expression in normal human lymphocytes in response to stimulation. Clin Diagn Lab Immunol 5: 335-340, 1998.
26. Germano G, Allavena P and Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374-379, 2008.
27. Dranoff G: Immune recognition and tumor protection. Curr Opin Immunol 14: 161-164, 2002.
28. Chow MT, Möller A and Smyth MJ: Inflammation and immune surveillance in cancer. Semin Cancer Biol 22: 23-32, 2012.
29. Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252, 2009.
30. Keibel A, Singh V and Sharma MC: Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 15: 1949-1955, 2009.
31. Rauch D, Gross S, Harding J, Bokhari S, Niewiesk S, et al: T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology 6: 116, 2009.
32. DeNardo DG and Coussens LM: Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212, 2007.